Mocht u de informatie op onze website kanker-actueel.nl waarderen dan wilt u ons misschien ondersteunen met een donatie

Ons rekeningnummer is: RABO 37.29.31.138 t.n.v. Stichting Gezondheid Actueel in Terneuzen. Onze IBANcode is NL79 RABO 0372 9311 38

Als donateur kunt u ook korting krijgen bij verschillende bedrijven. En we hebben een ANBI status.

1 februari 2020: lees ook dit artikel: 

https://kanker-actueel.nl/lenvatinib-plus-pembrolizumab-bij-patienten-met-gevorderde-baarmoederkanker-geeft-hoopgevende-resultaten-met-40-procent-remissies-van-50-procent-of-meer.html

31 januari 2020: Bron: Journal of Clinical Oncology

Bij patienten met solide tumoren waaronder gevorderde nierkanker, gevorderde baarmoederkanker, gevorderde melanomen waarbij geen operatie kan worden uitgevoerd of andere behandelingen hebben gefaald en er verder geen opties meer zijn blijkt de combinatie van Lenvatinib (een zogeheten VEGFR remmer - vascular endothelial growth factor receptors) en immuuntherapie met een anti-PD medicijn, in dit geval pembrolizumab, toch nog een veelbelovende behandelingsoptie.

In deze grafiek zijn de deelnemende patienten per vorm van kanker vermeld, hun status en of ze wel of niet PD-L1 expressie hadden ja of nee.:

View larger version (670K)

Uit het abstract overgenomen de resultaten op 2-jaars meting van een complete of gedeeltelijke remissie van 50 procent of meer:

  • nierkanker - RCC: 63% (19/30; 95% CI, 43.9% to 80.1%);
  • buikvlieskanker: 52% (12/23; 95% CI, 30.6% to 73.2%);
  • melanomen: 48% (10/21; 95% CI, 25.7% to 70.2%);
  • Hoofd-halstumoren - SCCHN: 36% (8/22; 95% CI, 17.2% to 59.3%);
  • Nier-kleincellige longkanker - NSCLC: 33% (7/21; 95% CI, 14.6% to 57.0%);
  • urinewegenkanker: 25% (5/20; 95% CI, 8.7% to 49.1%). 

De meest voorkomende behandelingsgerelateerde bijwerkingen waren vermoeidheid (58%), diarree (52%), hypertensie - te hoge bloeddruk (47%) en hypothyreoïdie = tekort aan schildklierhormonen (42%).

Het volledige studierapport: Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors is gratis in te zien.

Hier het abstract en daaronder de referentielijst:

The combination of lenvatinib plus pembrolizumab had promising efficacy among patients with selected solid tumors, with a manageable safety profile

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

, MD1, MD, PhD2, MD2, MD3, MD4, PhD4...Show More

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Modulation of vascular endothelial growth factor–mediated immune suppression via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We report results from the dose-finding and initial phase II expansion of a phase Ib/II study of lenvatinib plus pembrolizumab in patients with selected advanced solid tumors.

Eligible patients had metastatic renal cell carcinoma (RCC), endometrial cancer, squamous cell carcinoma of the head and neck (SCCHN), melanoma, non–small-cell lung cancer (NSCLC), or urothelial cancer. The primary objective of phase Ib was to determine the maximum tolerated dose (MTD) for lenvatinib plus pembrolizumab (200 mg intravenously every 3 weeks). In the preplanned phase II cohort expansion, the primary objective was objective response rate at week 24 (ORRweek 24) at the recommended phase II dose.

Overall, 137 patients were enrolled during phase Ib (n = 13) and the initial phase II expansion (n = 124). Two dose-limiting toxicities (DLTs; grade 3 arthralgia and grade 3 fatigue) were reported in the initial dose level (lenvatinib 24 mg/d plus pembrolizumab). No DLTs were observed in the subsequent dose–de-escalation cohort, establishing the MTD and recommended phase II dose at lenvatinib 20 mg/d plus pembrolizumab. ORRweek24 was as follows: RCC, 63% (19/30; 95% CI, 43.9% to 80.1%); endometrial cancer, 52% (12/23; 95% CI, 30.6% to 73.2%); melanoma, 48% (10/21; 95% CI, 25.7% to 70.2%); SCCHN, 36% (8/22; 95% CI, 17.2% to 59.3%); NSCLC, 33% (7/21; 95% CI, 14.6% to 57.0%); and urothelial cancer 25% (5/20; 95% CI, 8.7% to 49.1%). The most common treatment-related adverse events were fatigue (58%), diarrhea (52%), hypertension (47%), and hypothyroidism (42%).

Lenvatinib plus pembrolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with selected solid tumor types.

Conception and design: All authors

Provision of study materials or patients: Matthew H. Taylor, Robert J. Motzer, Chung-Han Lee, Vicky Makker, Drew Rasco

Collection and assembly of data: Matthew H. Taylor, Robert J. Motzer, Chung-Han Lee, Vicky Makker, Drew Rasco

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Matthew H. Taylor

Consulting or Advisory Role: Bristol-Myers Squibb, Eisai, Array BioPharma, Loxo, Bayer, ArQule, Blueprint Medicines, Novartis, Sanofi/Genzyme

Speakers' Bureau: Bristol-Myers Squibb, Eisai

Chung-Han Lee

Consulting or Advisory Role: Exelixis, Eisai, Amgen, Bristol-Myers Squibb

Research Funding: Pfizer (Inst), Eisai (Inst), Bristol-Myers Squibb (Inst), Calithera Biosciences (Inst), Exelixis (Inst)

Travel, Accommodations, Expenses: Eisai

Travel, Accommodations, Expenses: Calithera Biosciences

Vicky Makker

Honoraria: Eisai, Merck

Consulting or Advisory Role: Eisai, Merck, Karyopham, Takeda, ArQule

Research Funding: Lilly, AstraZeneca, Eisai, Merck, Takeda, Bristol-Myers Squibb

Travel, Accommodations, Expenses: Eisai, Merck, Karyopharm Therapeutics

Other Relationship: IBM

Drew Rasco

Consulting or Advisory Role: Boehringer Ingelheim, Lilly

Research Funding: Celgene (Inst), Millennium (Inst), Rexahn Pharmaceuticals (Inst), Five Prime Therapeutics (Inst), Pharmacyclics (Inst), Asana Biosciences (Inst), Eisai (Inst), Aeglea Biotherapeutics (Inst), Merck (Inst), Ascentage Pharma (Inst), Macrogenics (Inst), Apexian Pharmaceuticals (Inst), Birdie (Inst), AbbVie (Inst), Constellation Pharmaceuticals (Inst), Syndax (Inst), Astex Pharmaceuticals (Inst), Compugen (Inst), Coordination Therapeutics (Inst), GlaxoSmithKline (Inst), Incyte (Inst)

Travel, Accommodations, Expenses: Asana Biosciences

Corina E. Dutcus

Employment: Eisai

Jane Wu

Employment: Eisai

Daniel E. Stepan

Employment: Eisai

Robert C. Shumaker

Employment: Eisai, RRD International (I)

Robert J. Motzer

Consulting or Advisory Role: Pfizer, Novartis, Eisai, Exelixis, Merck, Genentech, Incyte, Lilly

Research Funding: Pfizer (Inst), Bristol-Myers Squibb (Inst), Eisai (Inst), Novartis (Inst), Genentech (Inst)

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT

We thank the patients, their families, the investigators, and the teams who participated in this trial. We also thank Emmett Schmidt, MD, PhD (Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ); Marcia Brose, MD, PhD (Department of Otorhinolaryngology – Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA); Peter Kubiak, PhD (Eisai Inc., Woodcliff Lake, NJ); and Lea Dutta, Pharm.D (Eisai Inc., Woodcliff Lake, NJ) for their contributions. This study was funded by Eisai Inc., Woodcliff Lake, NJ, and was also supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ. Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by a Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). Medical writing and editorial support was provided by Oxford PharmaGenesis Inc., Newtown, PA, and was funded by Eisai Inc., Woodcliff Lake, NJ, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ.

1. Fontanini GVignati SBoldrini L, et al: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3:861-8651997 MedlineGoogle Scholar
2. Sato KTsuchiya NSasaki R, et al: Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 90:874-8791999 CrossrefMedlineGoogle Scholar
3. Ott PAHodi FSBuchbinder EIInhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: An overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 5:2022015 CrossrefMedlineGoogle Scholar
4. Kato Y, Tabata K, Hori Y, et al: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors. Mol Cancer Ther 14, 2015 (12, suppl 2; abstr A92) Google Scholar
5. Kato Y: Upregulation of memory T cell population and enhancement of Th1 response by lenvatinib potentiate antitumor activity of PD-1 signaling blockade. Cancer Res 77, 2017 (13, suppl; abstr 4614) Google Scholar
6. Matsui JYamamoto YFunahashi Y, et al: E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664-6712008 CrossrefMedlineGoogle Scholar
7. Matsui JFunahashi YUenaka T, et al: Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14:5459-54652008 CrossrefGoogle Scholar
8. Tohyama OMatsui JKodama K, et al: Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:6387472014 CrossrefMedlineGoogle Scholar
9. Lieu CHeymach JOverman M, et al: Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 17:6130-61392011 CrossrefMedlineGoogle Scholar
10. Bergers GHanahan DModes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-6032008 CrossrefMedlineGoogle Scholar
11. Capozzi MDe Divitiis COttaiano A, et al: Lenvatinib, a molecule with versatile application: From preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 11:3847-38602019 CrossrefGoogle Scholar
12. Kato Y, Bao X, Macgrath S, et al: Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Ann Oncol 27, 2016 (suppl 6; abstr 2PD) Google Scholar
13. Medina PJAdams VRPD-1 pathway inhibitors: Immuno-oncology agents for restoring antitumor immune responses. Pharmacotherapy 36:317-3342016 CrossrefGoogle Scholar
14. Wolchok JDHoos AO’Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-74202009 CrossrefMedlineGoogle Scholar
15. Robert CSchachter JLong GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-25322015 CrossrefMedlineGoogle Scholar
16. Motzer RJHutson TEGlen H, et al: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473-14822015 CrossrefMedlineGoogle Scholar
17. Schlumberger MTahara MWirth LJ, et al: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621-6302015 CrossrefMedlineGoogle Scholar
18. Schlumberger MJarzab BCabanillas ME, et al: A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res 22:44-532016 CrossrefGoogle Scholar
19. Garon EBRizvi NAHui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-20282015 CrossrefMedlineGoogle Scholar
20. Herbst RSBaas PKim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-15502016 CrossrefMedlineGoogle Scholar
21. Patnaik AKang SPRasco D, et al: Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21:4286-42932015 CrossrefMedlineGoogle Scholar
22. Reck MRodríguez-Abreu DRobinson AG, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823-18332016 CrossrefMedlineGoogle Scholar
23. Bellmunt Jde Wit RVaughn DJ, et al: Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015-10262017 CrossrefMedlineGoogle Scholar
24. Kudo MFinn RSQin S, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 391:1163-11732018 CrossrefMedlineGoogle Scholar
25. McDermott DF, Lee J-L, Szczylik C, et al: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. J Clin Oncol 36, 2018 (15, suppl; abstr 4500) Google Scholar
26. Rini BIPlimack ERStus V, et al: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116-11272019 CrossrefGoogle Scholar
27. Motzer RJPenkov KHaanen J, et al: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103-11152019 CrossrefGoogle Scholar
28. Kato YTabata KKimura T, et al: Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One 14:e02125132019 CrossrefGoogle Scholar
29. Rini BIPowles TAtkins MB, et al: Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet 393:2404-24152019 CrossrefGoogle Scholar
30. Vergote ITeneriello MPowell MA, et al: A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes. J Clin Oncol 31:55202013 (15, suppl; abstr 5520Google Scholar
31. Ott PABang YJBerton-Rigaud D, et al: Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study. J Clin Oncol 35:2535-25412017 LinkGoogle Scholar
32. Kloor Mvon Knebel Doeberitz MThe immune biology of microsatellite-unstable cancer. Trends Cancer 2:121-1332016 CrossrefGoogle Scholar
33. Schachter JRibas ALong GV, et al: Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853-18622017 CrossrefMedlineGoogle Scholar
34. O’Day SGonzalez RKim K, et al: A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. J Clin Oncol 31 2013 (15, suppl; abstr 9026Google Scholar
35. Seiwert TYBurtness BMehra R, et al: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol 17:956-9652016 CrossrefMedlineGoogle Scholar
36. Larkins EBlumenthal GMYuan W, et al: FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist 22:873-8782017 CrossrefGoogle Scholar
37. Medical Dictionary for Drug Regulatory Affairs. www.meddra.org Google Scholar

Plaats een reactie ...

Reageer op "Lenvatinib Plus Pembrolizumab bij patiënten met inoperabele gevorderde nierkanker, baarmoederkanker, melanomen en andere gevorderde kanker met solide tumoren geeft uitstekende resultaten met meer dan de helft remissies van 50 procent of meer"


Gerelateerde artikelen
 

Gerelateerde artikelen

CRISPR-Cas9 gentherapie gericht >> Lenvatinib Plus Pembrolizumab >> Melanomen: Er is een sterk >> CAR-T cel therapie is een >> Immuuntherapie met het gemoduleerde >> Vaccin tegen KRAS positief >> pembrolizumab bij patiënten >> immuuntherapie met oncolytische >> Immuuntherapie met Gendicine >> Cryosurgery plus 1x ipilimumab >>